Arvinas, Inc. (ARVN)
After hours:
| Previous close | 32.26 |
| Open | 32.39 |
| Bid | 34.26 x 100 |
| Ask | 34.35 x 100 |
| Day's range | 31.90 - 34.77 |
| 52-week range | 13.57 - 53.08 |
| Volume | |
| Avg. volume | 748,745 |
| Market cap | 2.345B |
| Beta (5Y monthly) | 1.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.62 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 70.06 |
Simply Wall St.We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
ZacksArvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates
Arvinas (ARVN) delivered earnings and revenue surprises of 34.46% and 18.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireArvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for
